Peculiarities of Platelet Metabolism in Patients with Acute Coronary Syndrome with Anxiety–Depressive Disorders and Informativity of Enzymes in the Forecast of Development of Cardiovascular Complications

Figures

• 

  Figure 1. Activity of NADP-dependent platelet dehydrogenases in patients with acute coronary syndrome (ACS) without anxiety–depressive disorders (ADD), depending on the development of cardiovascular complications: (a) NADPH–GluDH activity; (b) NADP–MDH activity; (c) NADP–GluDH activity; (d) Glu6PDH activity; (e) NADP–ICDH activity. Notes: Data expressed as median and interquartile range (IQR), p < 0.05 was considered statistically significant. Wilcoxon matched-pairs test for patients without complications on the 1st vs. 10th day of the examination and for patients with complications on the 1st vs. 10th day of the examination. Mann–Whitney U test for patients vs. control and for patients with complications vs. patients without complications. Notes: µU—microunit.

• 

  Figure 2. Activity of NAD-dependent platelet dehydrogenases in patients with ACS without ADD, depending on the development of cardiovascular complications: (a) NADH–LDH activity; (b) NADH–MDH activity; (c) NAD–GluDH activity; (d) NAD–ICDH activity. Notes: Values expressed as median and interquartile range in the form of 25 and 75 percentiles, p < 0.05 was considered statistically significant. Wilcoxon matched-pairs test for patients without complications on the 1st vs. 10th day of the examination and for patients with complications on the 1st vs. 10th day of the examination. Mann–Whitney U test for patients vs. control subjects and for patients with complications vs. patients without complications. Notes: µU—microunit.

• 

  Figure 3. Activity of NADP-dependent platelet dehydrogenases in patients with ACS and ADD, depending on the development of complications: (a) NADP–GluDH activity; (b) NAD–ICDH activity; (c) NADP–MDH activity; (d) NADPH–GluDH activity; (e) Glu6PDH activity. Notes: Values expressed as median and interquartile range in the form of 25 and 75 percentiles, p < 0.05 was considered statistically significant. Wilcoxon matched-pairs rank test for patients without complications on the 1st vs. 10th day of the examination and for patients with complications on the 1st vs. 10th day of the examination. Mann–Whitney U test for patients vs. control subjects and for patients with complications vs. patients without complications. Notes: µU—microunit.

• 

  Figure 4. Activity of NAD-dependent platelet dehydrogenases in patients with ACS and ADD, depending on the development of complications: (a) NAD–GluDH activity; (b) NADH–MDH activity; (c) NADH–GluDH activity; (d) Gly3PDH activity; (e) LDH activity; (f) MDH activity. Notes: Values expressed as median and interquartile range in the form of 25 and 75 percentiles, p < 0.05 was considered statistically significant. Wilcoxon matched-pairs test for patients without complications on the 1st vs. 10th day of the examination and for patients with complications on the 1st vs. 10th day of the examination. Mann–Whitney U test for patients vs. control subjects and for patients with complications vs. patients without complications. Notes: µU—microunit.

• 

  Figure 5. Information content of NAD and NADP-dependent platelet dehydrogenases in the neural network classification in ACS patients with ADD in the prognosis of the development of cardiovascular complications. Notes: r.u.—relative units.